- Book学术

发布求助

文献互助智能选刊最新文献

IF 2.2 3区医学 Q3 ENGINEERING, BIOMEDICAL

Artificial organs Pub Date : 2025-03-31 DOI:10.1111/aor.14971

Boaz Elad, Changhee Lee, Julia Baranowska, Dor Lotan, Justin Fried, Kevin Clerkin, Jayant Raikhelkar, Andrea Fernandez Valledor, Cathrine M Moeller, Gabriel Sayer, Nir Uriel

{"title":"Vericiguat Experience in Durable Left Ventricular Assist Device Patients.","authors":"Boaz Elad, Changhee Lee, Julia Baranowska, Dor Lotan, Justin Fried, Kevin Clerkin, Jayant Raikhelkar, Andrea Fernandez Valledor, Cathrine M Moeller, Gabriel Sayer, Nir Uriel","doi":"10.1111/aor.14971","DOIUrl":null,"url":null,"abstract":"Introduction: Durable left ventricular assist devices (LVADs) improve outcomes for advanced heart failure (HF) patients. Vericiguat, which enhances HF outcomes by affecting systemic and pulmonary vasculature, may benefit LVAD patients as well.Methods: The study aimed to investigate the safety and efficacy of Vericiguat in patient on LVAD support. This retrospective analysis included patients supported with LVAD who were treated with Vericiguat. Safety outcomes comprised LVAD-related hemocompatibility-related adverse events (HRAE) and Vericiguat adverse events. Efficacy outcomes included changes in NYHA functional class and NT-proBNP levels.Results: We identified eight HeartMate3 patients treated with Vericiguat. Median age was 65 years-old, 87.5% were men, and median duration on Vericiguat therapy was 254 days (161-272). None of the patients had experienced HRAE, adverse events related to Vericiguat or died. A reduction in pulmonary capillary wedge pressure was observed (17 [16-23.5] vs. 9 [6.5-11] mmHg, p = 0.06), along with an increase in cardiac index (from 1.9 [1.5-2.6] to 2.1 [1.8-3.2] L/min/m2, p = 0.12) and right ventricle stroke work index (5.4 [4.1, 7.0] vs. 7.5 [6.9, 9.2] g/m/beat/m2, p = 0.043). NT-proBNP levels (2171 [779-3366] vs. 1677 [406-2490] pg/mL, p = 0.438) decreased but did not reach statistical significance.Conclusions: Preliminary results suggests that Vericiguat therapy in LVADs is safe and indicates a trend toward improved efficacy.","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/aor.14971","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

摘要

导言：耐用的左心室辅助装置（LVAD）可改善晚期心力衰竭（HF）患者的预后。韦立克通过影响全身和肺血管来改善心力衰竭的预后，可能也会使 LVAD 患者受益：该研究旨在调查维力青在接受 LVAD 支持的患者中的安全性和有效性。这项回顾性分析纳入了接受韦立克治疗的 LVAD 患者。安全性结果包括与 LVAD 相关的血液相容性不良事件 (HRAE) 和 Vericiguat 不良事件。疗效结果包括 NYHA 功能分级和 NT-proBNP 水平的变化：我们发现了 8 名接受过 Vericiguat 治疗的 HeartMate3 患者。中位年龄为 65 岁，87.5% 为男性，接受韦立克治疗的中位时间为 254 天（161-272 天）。所有患者均未出现 HRAE、与韦立吉特相关的不良事件或死亡。观察到肺毛细血管楔压降低（17 [16-23.5] vs. 9 [6.5-11] mmHg，p = 0.06），心脏指数上升（从 1.9 [1.5-2.6] 升至 2.1 [1.8-3.2] 升/分钟/平方米，p = 0.12）和右心室搏动功指数（5.4 [4.1, 7.0] vs. 7.5 [6.9, 9.2] 克/米/搏动/平方米，p = 0.043）。NT-proBNP水平（2171 [779-3366] vs. 1677 [406-2490] pg/mL，p = 0.438）有所下降，但未达到统计学意义：初步结果表明，在 LVAD 中使用 Vericiguat 治疗是安全的，并显示出疗效改善的趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Vericiguat Experience in Durable Left Ventricular Assist Device Patients.

Introduction: Durable left ventricular assist devices (LVADs) improve outcomes for advanced heart failure (HF) patients. Vericiguat, which enhances HF outcomes by affecting systemic and pulmonary vasculature, may benefit LVAD patients as well.

Methods: The study aimed to investigate the safety and efficacy of Vericiguat in patient on LVAD support. This retrospective analysis included patients supported with LVAD who were treated with Vericiguat. Safety outcomes comprised LVAD-related hemocompatibility-related adverse events (HRAE) and Vericiguat adverse events. Efficacy outcomes included changes in NYHA functional class and NT-proBNP levels.

Results: We identified eight HeartMate3 patients treated with Vericiguat. Median age was 65 years-old, 87.5% were men, and median duration on Vericiguat therapy was 254 days (161-272). None of the patients had experienced HRAE, adverse events related to Vericiguat or died. A reduction in pulmonary capillary wedge pressure was observed (17 [16-23.5] vs. 9 [6.5-11] mmHg, p = 0.06), along with an increase in cardiac index (from 1.9 [1.5-2.6] to 2.1 [1.8-3.2] L/min/m², p = 0.12) and right ventricle stroke work index (5.4 [4.1, 7.0] vs. 7.5 [6.9, 9.2] g/m/beat/m², p = 0.043). NT-proBNP levels (2171 [779-3366] vs. 1677 [406-2490] pg/mL, p = 0.438) decreased but did not reach statistical significance.

Conclusions: Preliminary results suggests that Vericiguat therapy in LVADs is safe and indicates a trend toward improved efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Artificial organs 工程技术-工程：生物医学

CiteScore

4.30

自引率

12.50%

发文量

303

审稿时长

4-8 weeks

期刊介绍： Artificial Organs is the official peer reviewed journal of The International Federation for Artificial Organs (Members of the Federation are: The American Society for Artificial Internal Organs, The European Society for Artificial Organs, and The Japanese Society for Artificial Organs), The International Faculty for Artificial Organs, the International Society for Rotary Blood Pumps, The International Society for Pediatric Mechanical Cardiopulmonary Support, and the Vienna International Workshop on Functional Electrical Stimulation. Artificial Organs publishes original research articles dealing with developments in artificial organs applications and treatment modalities and their clinical applications worldwide. Membership in the Societies listed above is not a prerequisite for publication. Articles are published without charge to the author except for color figures and excess page charges as noted.